Sponsored Links
| VIA Pharmaceuticals Completes Patient Visits In Phase 2 Trial Of VIA-2291 |
 |
 |
 |
| Pharmacy - Pharma Industry - Biotech Industry | |||
|
VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, announced that it has completed the last patient visit in its Phase 2 FDG-PET clinical trial of VIA-2291... Read more: Pharma Industry / Biotech Industry News From Medical News Today
|